(Total Views: 326)
Posted On: 03/30/2019 12:59:29 PM
Post# of 72446
Another gigantic cancer treatment deal:
https://finance.yahoo.com/news/astrazeneca-se...43989.html
1.35 billion upfront.
5.6 billion in milestones.
"Projected to rake in $7 billion annually at its peak, Daiichi’s treatment has been seen to double survival time for advanced breast cancer patients to 20 months from 10 "
All that for a treatment that adds 10 months survival to breast cancer patients.
The bar is low for Kevetrin. Any sign of efficacy from an oral Kevetrin treatment should rocket our valuation into orbit.
https://finance.yahoo.com/news/astrazeneca-se...43989.html
1.35 billion upfront.
5.6 billion in milestones.
"Projected to rake in $7 billion annually at its peak, Daiichi’s treatment has been seen to double survival time for advanced breast cancer patients to 20 months from 10 "
All that for a treatment that adds 10 months survival to breast cancer patients.
The bar is low for Kevetrin. Any sign of efficacy from an oral Kevetrin treatment should rocket our valuation into orbit.
(0)
(0)
